{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SoC&page=18", "query": { "intervention": "SoC", "page": 18 }, "page_size": 10 }, "pagination": { "page": 18, "page_size": 10, "total_count": 1401, "total_pages": 141, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SoC&page=19&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SoC&page=17&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-25T02:44:17.595Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05945290", "title": "Pre-analytical Factors Affecting ctDNA Analysis in Early and Locally Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "Early Stage Breast Carcinoma", "Locally Advanced Breast Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Electronic Health Record Review", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 114, "start_date": "2022-07-07", "completion_date": "2025-06-16", "has_results": false, "last_update_posted_date": "2025-09-09", "last_synced_at": "2026-10-25T02:44:17.595Z", "location_count": 1, "location_summary": "Scottsdale, Arizona", "locations": [ { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05945290" }, { "nct_id": "NCT07740317", "title": "Neurocognitive Trajectories After BCMA CAR-T", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Multiple Myeloma (MM)", "CART Therapy", "Refractory Multiple Myeloma (RRMM)" ], "interventions": [ { "name": "Standardized neurocognitive testing", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2026-11", "completion_date": "2029-11", "has_results": false, "last_update_posted_date": "2026-10-23", "last_synced_at": "2026-10-25T02:44:17.595Z", "location_count": 1, "location_summary": "Charlotte, North Carolina", "locations": [ { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07740317" }, { "nct_id": "NCT06910813", "title": "DFT383 in Pediatric Participants With Nephropathic Cystinosis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Nephropathic Cystinosis" ], "interventions": [ { "name": "DFT383", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "5 Years", "sex": "ALL", "summary": "2 Years to 5 Years" }, "enrollment_count": 30, "start_date": "2025-06-02", "completion_date": "2044-05-28", "has_results": false, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-10-25T02:44:17.595Z", "location_count": 6, "location_summary": "Phoenix, Arizona • San Diego, California • Stanford, California + 3 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06910813" }, { "nct_id": "NCT07782970", "title": "A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) in Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Nasal Polyps" ], "interventions": [ { "name": "GSK5784283", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Standard of Care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 218, "start_date": "2026-09-28", "completion_date": "2029-10-30", "has_results": false, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-10-25T02:44:17.595Z", "location_count": 2, "location_summary": "Los Angeles, California • Tulsa, Oklahoma", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Tulsa", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT07782970" }, { "nct_id": "NCT06998524", "title": "A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Von Willebrand Disease, Type 3" ], "interventions": [ { "name": "Emicizumab", "type": "DRUG" }, { "name": "von Willebrand Factor (VWF) Concentrates", "type": "DRUG" }, { "name": "Factor VIII (FVIII) Concentrates", "type": "DRUG" }, { "name": "von Willebrand Factor (VWF) and Factor VIII (FVIII) Concentrates", "type": "DRUG" }, { "name": "Bypassing Agents", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Month", "maximum_age": null, "sex": "ALL", "summary": "1 Month and older" }, "enrollment_count": 75, "start_date": "2025-06-27", "completion_date": "2029-04-30", "has_results": false, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-10-25T02:44:17.595Z", "location_count": 6, "location_summary": "Sacramento, California • Gainesville, Florida • Lexington, Kentucky + 3 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT06998524" }, { "nct_id": "NCT03403205", "title": "Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Wilson Disease" ], "interventions": [ { "name": "ALXN1840", "type": "DRUG" }, { "name": "SoC Therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alexion Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 214, "start_date": "2018-02-22", "completion_date": "2023-06-30", "has_results": true, "last_update_posted_date": "2024-06-17", "last_synced_at": "2026-10-25T02:44:17.595Z", "location_count": 6, "location_summary": "Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03403205" }, { "nct_id": "NCT04962191", "title": "Idylla EGFR Lung Trial", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Lung Cancer", "Technology", "Oncology" ], "interventions": [ { "name": "Idylla EGFR Mutation Test", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Anthony Magliocco", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2021-08", "completion_date": "2023-01", "has_results": false, "last_update_posted_date": "2021-07-14", "last_synced_at": "2026-10-25T02:44:17.595Z", "location_count": 1, "location_summary": "Orlando, Florida", "locations": [ { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04962191" }, { "nct_id": "NCT03563170", "title": "QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma Non-resectable", "Hepatocellular Carcinoma Recurrent" ], "interventions": [ { "name": "ETBX-011", "type": "BIOLOGICAL" }, { "name": "GI-4000", "type": "BIOLOGICAL" }, { "name": "haNK for infusion", "type": "BIOLOGICAL" }, { "name": "avelumab", "type": "BIOLOGICAL" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "nab-Paclitaxel", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" }, { "name": "SBRT", "type": "PROCEDURE" }, { "name": "Aldoxorubicin hydrochloride", "type": "BIOLOGICAL" }, { "name": "ETBX-051", "type": "BIOLOGICAL" }, { "name": "ETBX-061", "type": "BIOLOGICAL" }, { "name": "GI-6207", "type": "BIOLOGICAL" }, { "name": "GI-6301", "type": "BIOLOGICAL" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "N-803", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2018-05-25", "completion_date": "2019-08-23", "has_results": false, "last_update_posted_date": "2021-03-18", "last_synced_at": "2026-10-25T02:44:17.595Z", "location_count": 1, "location_summary": "El Segundo, California", "locations": [ { "city": "El Segundo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03563170" }, { "nct_id": "NCT02732327", "title": "Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms", "Febrile Neutropenia" ], "interventions": [ { "name": "CAZ-AVI", "type": "DRUG" }, { "name": "Vancomycin", "type": "DRUG" }, { "name": "Linezolid", "type": "DRUG" }, { "name": "Cefepime", "type": "DRUG" }, { "name": "Meropenem", "type": "DRUG" }, { "name": "Piperacillin/tazobactam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Forest Laboratories", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2016-05-17", "completion_date": "2016-06-27", "has_results": true, "last_update_posted_date": "2017-07-21", "last_synced_at": "2026-10-25T02:44:17.595Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02732327" }, { "nct_id": "NCT06805305", "title": "DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma (GBM)" ], "interventions": [ { "name": "DOC1021", "type": "BIOLOGICAL" }, { "name": "Tumor resection", "type": "PROCEDURE" }, { "name": "Temodar (Temozolomide)", "type": "DRUG" }, { "name": "SOC cranial radiation", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG", "RADIATION" ], "sponsor": "Diakonos Oncology Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 180, "start_date": "2025-03-17", "completion_date": "2032-03", "has_results": false, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-10-25T02:44:17.595Z", "location_count": 18, "location_summary": "Gilbert, Arizona • Duarte, California • Newport Beach, California + 14 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06805305" } ] }